Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Oncología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 3
ClinicalTrials.gov
An Open-label, Multi-center, Three Arm Randomized Study to Investigate the Safety and Efficacy on Progression-free Survival of RO5072759 + Chlorambucil (GClb) Compared to Rituximab + Chlorambucil (RClb) or Chlorambucil (Clb) Alone in Previously Untreated CLL Patients With Comorbidities.
INTERVENTIONAL
Inicio: 21 de dic de 2009
ID: NCT01010061
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor
INTERVENTIONAL
Inicio: 12 de abr de 2021
ID: NCT04576156
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer
INTERVENTIONAL
Inicio: 6 de feb de 2020
ID: NCT04100018
Completado
Fase 2
ClinicalTrials.gov
Open Clinical Trial, Uncontrolled in Patients Bearing Squamous Cell Carcinoma or Adenocarcinoma of the Cervix Stage IIA and IIB FIGO Classification Treated With Radiotherapy External Endocavitary Brachytherapy + Concurrent Hemotherapy Weekly Systemic and Local Application of CIGB-300 Dose Escalation
INTERVENTIONAL
Inicio: 1 de may de 2011
ID: NCT01639625
Completado
Fase 3
ClinicalTrials.gov
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
INTERVENTIONAL
Inicio: 1 de ago de 2006
ID: NCT00324155
Reclutando
Fase 2
ClinicalTrials.gov
A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastic Breast Cancer After Progression on Previous Endocrine Therapy (LITESPARK-029)
INTERVENTIONAL
Inicio: 27 de nov de 2024
ID: NCT06428396
Completado
Fase 3
ClinicalTrials.gov
A LARGE-SCALE TRIAL EVALUATING ADJUVANT CHEMOTHERAPY AFTER CURATIVE RESECTION OF NON-SMALL CELL LUNG CANCER
INTERVENTIONAL
Inicio: 1 de feb de 1995
ID: NCT00002823
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
INTERVENTIONAL
Inicio: 14 de oct de 2021
ID: NCT05083169
Completado
Fase 3
ClinicalTrials.gov
Randomized Double-Blind Trial In Postmenopausal Women With Primary Breast Cancer Who Have Received Adjuvant Tamoxifen For 2-3 Years, Comparing Subsequent Adjuvant Exemestane Treatment With Further Tamoxifen
INTERVENTIONAL
Inicio: 1 de feb de 1998
ID: NCT00038467
Terminado
Fase 2
ClinicalTrials.gov
A Randomized, Open Label, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Lumiliximab in Combination With Fludarabine, Cyclophosphamide, and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia
INTERVENTIONAL
Inicio: 1 de nov de 2006
ID: NCT00391066
Terminado
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women With Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE)
INTERVENTIONAL
Inicio: 2 de jun de 2010
ID: NCT01077154
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer
INTERVENTIONAL
Inicio: 14 de jun de 2018
ID: NCT03493854
Completado
Fase 1
ClinicalTrials.gov
Phase 1 Study on the Use of Racotumomab Anti-idiotype Antibody in Patients With Pediatric Malignancies That Express N-glycolylated Gangliosides and Are Resistant to Conventional Treatment.
INTERVENTIONAL
Inicio: 1 de feb de 2011
ID: NCT01598454
Reclutando
Fase 3
ClinicalTrials.gov
Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Mocravimod as Adjunctive and Maintenance Treatment in Adult AML Patients Undergoing Allogeneic HCT
INTERVENTIONAL
Inicio: 16 de jun de 2022
ID: NCT05429632
Reclutando
Fase 3
ClinicalTrials.gov
Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab
INTERVENTIONAL
Inicio: 15 de mar de 2023
ID: NCT05445778
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
INTERVENTIONAL
Inicio: 16 de oct de 2014
ID: NCT02231749
Reclutando
Fase 3
ClinicalTrials.gov
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
INTERVENTIONAL
Inicio: 23 de nov de 2023
ID: NCT06103864
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Randomized, Phase 3, Open-label Study to Evaluate Sigvotatug Vedotin Compared With Docetaxel in Adult Participants With Previously Treated Non-small Cell Lung Cancer (Be6A Lung-01)
INTERVENTIONAL
Inicio: 21 de feb de 2024
ID: NCT06012435
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
INTERVENTIONAL
Inicio: 28 de sept de 2020
ID: NCT04543617
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab Compared With Chemotherapy in Patients With Treatment Naïve Advanced or Recurrent (Stage IIIb Not Amenable for Multimodality Treatment) or Metastatic (Stage IV) Non-Small Cell Lung Cancer Who Are Deemed Unsuitable for Platinum-Containing Therapy
INTERVENTIONAL
Inicio: 11 de sept de 2017
ID: NCT03191786
Anterior
1
...
62
63
64
...
434
Siguiente
Filtros